European Expansion And Operational Improvements Will Unlock Cannabis Potential

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

31 Mar 25

Updated

24 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-68.8%

7D

-1.8%

Loading

1Y

-68.8%

7D

-1.8%

You can edit this narrative until Nov 25 10:05 PM. Then, changes will post as Updates.

Author's Valuation

CA$3.351.5% undervalued

AnalystConsensusTarget Fair Value

Shared on 24 Nov 25

Fair value Increased 154%

WEED: Improving Profit Margins And Share Consolidation Will Drive Future Upside

Analysts have raised their price target for Canopy Growth from $1.30 to $3.30. They cite improvements in profit margin projections and expectations of sustained profitability, despite moderated revenue growth forecasts.

Shared on 10 Nov 25

Fair value Decreased 51%

WEED: Rising Discount Rate Will Pressure Share Price In The Months Ahead

Analysts have adjusted their price target for Canopy Growth downward from $2.64 to $1.30. They cited an increased discount rate as well as ongoing evaluations of profit margin and future earnings potential.

Shared on 07 Aug 25

Fair value Decreased 20%

Consensus analyst price targets for Canopy Growth have been revised lower primarily due to a marked slowdown in forecast revenue growth, resulting in a fair value decrease from CA$3.31 to CA$2.98. What's in the News Canopy Growth introduced its Canadian-grown 7ACRES brand in Australia, expanding its medical cannabis portfolio with high-THC sativa strains Ultra Jack and Jack Frost.

Shared on 01 May 25

Fair value Decreased 8.19%

Shared on 24 Apr 25

AnalystConsensusTarget has increased profit margin from 0.7% to 1.1% and decreased future PE multiple from 458.9x to 291.0x.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 17%

AnalystConsensusTarget has increased discount rate from 6.7% to 7.4%.

Shared on 02 Apr 25

Fair value Increased 7.50%

AnalystConsensusTarget Fair Value

CA$3.3

51.5% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

5.52%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

6.12%

Calculation

CA$18.05m

Earnings '28

x

164.25x

PE Ratio '28

=

CA$2.96b

Market Cap '28

CA$2.96b

Market Cap '28

/

751.80m

No. shares '28

=

CA$3.94

Share Price '28

CA$3.94 Share Price '28

Discounted to 2025 @ 6.12% p.a.

=

CA$3.30

Fair Value '25